SarcopeniaNCT05148351
Validity of an App to Detect Frailty and Sarcopenia Syndromes in Elderly
An observational study of Sarcopenia and Frailty Syndrome, run by Catholic University of Murcia at 1 site in Spain.
Trial summary
Frailty and sarcopenia are two age-related syndromes which can result in adverse health-related events. The combination of both is more predictive of mortality than either condition alone. These conditions can be reversed through an early detection and appropriate interventions. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia, Frailty Syndrome, Aging
- How many people
- 775 participants
- Where
- 1 siteSpain
- Study dates
- 17 Feb 2022to 1 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: At least 400 community-dwelling older adults, older than 60 y/o and living in the Region of Murcia (Spain) will be recruited.
Who may be able to join
- Community-dwelling older adults living in the Region of Murcia
Who cannot join
- Barthel Index < 90 pts.
- Mini-Cog test < 3 pts.
- Severe cardiovascular problems
- Pacemaker
- Automatic defibrillator
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Validity of an iPhone App to Detect Frailty and Sarcopenia Syndromes in Community Dwelling Older Adults: Protocol for a Diagnostic Accuracy Study
Frailty and sarcopenia are two age-related syndromes which can result in adverse health-related events. The combination of both is more predictive of mortality than either condition alone. These conditions can be reversed through an early detection and appropriate interventions. Nevertheless, scientific community highlights the lack of cheap, portable, rapid and easy-to-use tools for detecting frailty and sarcopenia in combination. The aim of this study is to validate an iPhone App to detect frailty and sarcopenia syndromes in community dwelling older adults. This is a protocol study of a retrospective diagnostic test accuracy study which will include at least 400 participants older than 60 years recruited from elderly social centers of Murcia city. Researchers will recollect data of health status, dependency, cognitive status, and functional capacity of the participants. The index test will consist in the measurement of muscle power exerted during a single Sit-to-stand through an App (iPhone), combined with calf and mid-upper arm circumference. The reference standard will be frailty syndrome and sarcopenia assessed according to Fried's phenotype and to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) (2019) recommendations, respectively. Sensitivity, specificity, positive predictive value, negative predictive values, and area under the curve will be reported.
- Conditions
- Sarcopenia, Frailty Syndrome, Aging, Aged, Diagnosis
- Keywords
- Functional Capacity, Sit-to-Stand Test, Muscle Power, Chair rise
- Medical subject headings
- Sarcopenia, Frailty, Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscular power
Muscular power generated by participants will be measured using an App (Sit-to-stand App version 1.1) installed on an iPhone (Apple Inc., USA).
During the execution, subjects will sit on a rigid chair with their arms crossed over their chest with the hip, knee and ankle joints at approximately 90 degrees. Subjects will be asked to stand-up as fast as possible. Participants will complete three STS repetitions. No footwear will be allowed during the test.
Measured: Cross-sectional baseline
Frailty Syndrome
Frailty Syndrome will be assessed according to Fried's Phenotype, which focuses on:
- Handgrip strength
- Usual gait speed
- Weight loss
- Exhaustion
- Physical activity levels
Subjects who will result positive to three out of five criteria will be considered as "frail", whereas if they will result positive to only one or two of them they will be considered as "pre-frail". The absence of each criteria will be necessary to define a subject as "robust".
Measured: Cross-sectional baseline
Sarcopenia
Sarcopenia will be assessed according to the recommendation provided by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) (2019). This guideline focuses on the assessment of:
- Leg muscle strength
- Muscle mass quantity
- Physical performance
The presence of low muscle strength levels will be considered as "probable sarcopenia"; the presence of low muscle mass and strength levels will be considered as "confirmed sarcopenia"; finally, the presence of the three criteria will be considered as "severe sarcopenia".
Measured: Cross-sectional baseline
Calf and mid-upper arm circumference
Researchers will measure subjects' calf and mid-upper arm circumference using a tape measure.
Measured: Cross-sectional baseline
Secondary outcomes (1)
Subjects' clinical status
Subjects' clinical status will be assessed through a list of questions regarding:
- socioeconomic level
- educational level
- chronic pathologies
- smoking habits
- polypharmacy
- depression
- number of falls
- hospitalization
- self-perceived health status
Measured: Cross-sectional baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2021
- Study start17 Feb 2022
- Primary completion1 Oct 2022
- Study completion1 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 775 participants (actual)
Sponsor and investigators
- Lead sponsor
- Catholic University of Murcia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alessio Montemurro, Catholic University of Murcia
- Investigators
- Juan D Ruiz-Cárdenas, Study director, Catholic University of Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05148351
- Sponsor's protocol ID
- Universidad Católica de Murcia
- Status last verified
- Oct 2022
- First submitted
- 25 Nov 2021
- Last updated
- 24 Oct 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ruiz-Cardenas JD, Rodriguez-Juan JJ, Martinez-Garcia MDM, Montemurro A. Comparing Sarcopenia Definitions and Muscle Power Reduction: Associations with Health Outcomes in Spanish Community-Dwelling Older Adults. J Clin Med. 2024 Aug 23;13(17):4988. doi: 10.3390/jcm13174988.
PubMed 39274199Ruiz-Cardenas JD, Montemurro A, Martinez-Garcia MDM, Rodriguez-Juan JJ. Sit-to-Stand Video Analysis-Based App for Diagnosing Sarcopenia and Its Relationship With Health-Related Risk Factors and Frailty in Community-Dwelling Older Adults: Diagnostic Accuracy Study. J Med Internet Res. 2023 Dec 8;25:e47873. doi: 10.2196/47873.
PubMed 38064268Montemurro A, Ruiz-Cardenas JD, Martinez-Garcia MDM, Rodriguez-Juan JJ. Validity of an iPhone App to Detect Prefrailty and Sarcopenia Syndromes in Community-Dwelling Older Adults: The Protocol for a Diagnostic Accuracy Study. Sensors (Basel). 2022 Aug 11;22(16):6010. doi: 10.3390/s22166010.
PubMed 36015771
Study at a glance
From the registry record, last updated by the sponsor on 24 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validity of an iPhone App to Detect Frailty and Sarcopenia Syndromes in Community Dwelling Older Adults: Protocol for a Diagnostic Accuracy Study
- ClinicalTrials.gov ID
- NCT05148351
- Acronym / sponsor ID
- Universidad Católica de Murcia
- Conditions
- Sarcopenia, Frailty Syndrome, Aging, Aged, Diagnosis
- Keywords
- Functional Capacity, Sit-to-Stand Test, Muscle Power, Chair rise
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 775 participants (actual)
- Lead sponsor
- Catholic University of MurciaUniversity, hospital or other
- Study start
- 17 Feb 2022 (actual)
- Primary completion
- 1 Oct 2022 (actual)
- Study completion
- 1 Oct 2022 (actual)
- First posted
- 8 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Frailty and sarcopenia are two age-related syndromes which can result in adverse health-related events. The combination of both is more predictive of mortality than either condition alone. These conditions can be reversed through an early detection and appropriate interventions. Nevertheless, scientific community highlights the lack of cheap, portable, rapid and easy-to-use tools for detecting frailty and sarcopenia in combination. The aim of this study is to validate an iPhone App to detect frailty and sarcopenia syndromes in community dwelling older adults. This is a protocol study of a retrospective diagnostic test accuracy study which will include at least 400 participants older than 60 years recruited from elderly social centers of Murcia city. Researchers will recollect data of health status, dependency, cognitive status, and functional capacity of the participants. The index test will consist in the measurement of muscle power exerted during a single Sit-to-stand through an App (iPhone), combined with calf and mid-upper arm circumference. The reference standard will be frailty syndrome and sarcopenia assessed according to Fried's phenotype and to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) (2019) recommendations, respectively. Sensitivity, specificity, positive predictive value, negative predictive values, and area under the curve will be reported.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- At least 400 community-dwelling older adults, older than 60 y/o and living in the Region of Murcia (Spain) will be recruited.
Key inclusion criteria (1 listed)
- Community-dwelling older adults living in the Region of Murcia
Key exclusion criteria (5 listed)
- Barthel Index < 90 pts.
- Mini-Cog test < 3 pts.
- Severe cardiovascular problems
- Pacemaker
- Automatic defibrillator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Muscular power
Time frame: Cross-sectional baseline
Muscular power generated by participants will be measured using an App (Sit-to-stand App version 1.1) installed on an iPhone (Apple Inc., USA). During the execution, subjects will sit on a rigid chair with their arms crossed over their chest with the hip, knee and ankle joints at approximately 90 degrees. Subjects will be asked to stand-up as fast as possible. Participants will complete three STS repetitions. No footwear will be allowed during the test.
Frailty Syndrome
Time frame: Cross-sectional baseline
Frailty Syndrome will be assessed according to Fried's Phenotype, which focuses on: 1. Handgrip strength 2. Usual gait speed 3. Weight loss 4. Exhaustion 5. Physical activity levels Subjects who will result positive to three out of five criteria will be considered as "frail", whereas if they will result positive to only one or two of them they will be considered as "pre-frail". The absence of each criteria will be necessary to define a subject as "robust".
Sarcopenia
Time frame: Cross-sectional baseline
Sarcopenia will be assessed according to the recommendation provided by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) (2019). This guideline focuses on the assessment of: 1. Leg muscle strength 2. Muscle mass quantity 3. Physical performance The presence of low muscle strength levels will be considered as "probable sarcopenia"; the presence of low muscle mass and strength levels will be considered as "confirmed sarcopenia"; finally, the presence of the three criteria will be considered as "severe sarcopenia".
Calf and mid-upper arm circumference
Time frame: Cross-sectional baseline
Researchers will measure subjects' calf and mid-upper arm circumference using a tape measure.
1 secondary outcome
Subjects' clinical status
Time frame: Cross-sectional baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Oct 2022.
- Derived from this study: PubMed 39274199Ruiz-Cardenas JD, Rodriguez-Juan JJ, Martinez-Garcia MDM, Montemurro A. Comparing Sarcopenia Definitions and Muscle Power Reduction: Associations with Health Outcomes in Spanish Community-Dwelling Older Adults. J Clin Med. 2024 Aug 23;13(17):4988. doi: 10.3390/jcm13174988.
- Derived from this study: PubMed 38064268Ruiz-Cardenas JD, Montemurro A, Martinez-Garcia MDM, Rodriguez-Juan JJ. Sit-to-Stand Video Analysis-Based App for Diagnosing Sarcopenia and Its Relationship With Health-Related Risk Factors and Frailty in Community-Dwelling Older Adults: Diagnostic Accuracy Study. J Med Internet Res. 2023 Dec 8;25:e47873. doi: 10.2196/47873.
- Derived from this study: PubMed 36015771Montemurro A, Ruiz-Cardenas JD, Martinez-Garcia MDM, Rodriguez-Juan JJ. Validity of an iPhone App to Detect Prefrailty and Sarcopenia Syndromes in Community-Dwelling Older Adults: The Protocol for a Diagnostic Accuracy Study. Sensors (Basel). 2022 Aug 11;22(16):6010. doi: 10.3390/s22166010.
- Individual participant dataSharing planned: No
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juan D Ruiz-Cárdenas study director
Catholic University of Murcia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia and Frailty Syndrome, run by Catholic University of Murcia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Muscular power (time frame: Cross-sectional baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05148351, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2022.